Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could your gut and kidneys be affecting your brain? new MRI study investigates

NCT ID NCT07617402

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at why people with IgA nephropathy (a kidney disease) often experience memory and attention problems. Researchers used powerful 7-Tesla MRI scanners to examine the brains of 100 patients and 100 healthy volunteers, along with analyzing their gut bacteria and blood. The goal was to uncover how the brain, gut, and kidneys might interact to cause cognitive decline, which could lead to better treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify early brain injury markers and gut microbiome changes linked to cognitive decline in IgA nephropathy, pointing toward future interventions.
What could go wrong
This is an observational study, not a treatment trial. It aims to understand mechanisms, not test a therapy. Results may not lead directly to clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Apr 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

IgA Nephropathy (IgAN) Group: A cohort of 100 patients diagnosed with IgA nephropathy, confirmed by pathological biopsy. Healthy Control (HC) Group: A cohort of 100 healthy volunteers who are demographically matched to the patient group in terms of age, gender, and educational attainment.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Right-handed individuals, age 18-60 years; 2. Diagnosis of IgA nephropathy confirmed by renal biopsy. Exclusion Criteria: 1. Secondary IgA nephropathy, such as that associated with systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, hepatitis B or C infection, or drug-induced causes. 2. History of kidney transplantation, hemodialysis, or peritoneal dialysis. 3. Acute cerebrovascular event within the past 3 months; a history of severe traumatic brain injury, brain tumor, stroke, or encephalomalacia that has resulted in identifiable lesions or significant asymmetry of cranial anatomy. 4. Malignant tumors; a history of intestinal surgery; or irritable bowel syndrome (IBS). 5. Use of antibiotics, steroids, immunosuppressants, or microbiota-based preparations within the past month. 6. Inflammatory bowel disease (IBD); or the presence of symptoms such as diarrhea, abdominal pain, or IBS-like symptoms within the past two weeks. 7. History of alcohol dependence. 8. Current use of psychiatric medications, such as antidepressants or anxiolytics. 9. Loss of hearing or vision. 10. Pregnancy or lactation. 11. Current participation in another clinical trial. Contraindications for 7.0T MRI Presence of ferromagnetic implants in the body (e.g., cardiac pacemakers, defibrillators, neurostimulators, aneurysm clips, cochlear implants, or any other metallic foreign bodies). Non-ferromagnetic implants (e.g., titanium alloy, orthopedic implants), intrauterine devices (IUDs), or non-removable dental prosthetics (including dental implants). Metallic foreign bodies in the eye or body (e.g., metal fragments, shrapnel, or metallic debris), such as in individuals with a history of welding or metal-related injuries. Tattoos or permanent makeup (e.g., on eyebrows or lips) acquired within the last month. Claustrophobia. Fever. Inclusion Criteria for the Healthy Control Group All healthy controls must meet the following criteria: 1. Right-handed, aged 18-60 years; 2. All physiological indicators within the normal range, with no signs of disease; 3. No family history of psychiatric or neurological disorders. Exclusion Criteria for the Healthy Control Group 1. History of cranial surgery, brain tumor, traumatic brain injury, stroke, or encephalomalacia resulting in significant asymmetry of cranial anatomy; 2. History of psychiatric disorders, alcohol dependence, or central nervous system diseases; 3. Presence of metallic foreign bodies in the body or claustrophobia, making them unsuitable for MRI scanning; 4. History of hypertension, diabetes, or hyperlipidemia; 5. Hearing or vision impairment that would affect communication during the MRI scan or the completion of cognitive assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IgA nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Functional and Molecular Imaging Key Lab of Shaanxi Province, Department of Radiology, Tangdu Hospital, Fourth Military Medical University

    Shanxi, Xi'an, 713800, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.